Main Title |
Regulatory impact assessment of proposed effluent guidelines for the pharmaceutical manufacturing industry : final report. |
CORP Author |
Environmental Protection Agency, Washington, DC. Office of Water. |
Publisher |
U.S. Environmental Protection Agency, Engineering and Analysis Division, Office of Science and Technology, Office of Water, |
Year Published |
1995 |
Report Number |
EPA 821-R-95-017 |
Stock Number |
PB95-219812 |
OCLC Number |
33149395 |
Subjects |
Drug factories--Waste disposal--Standards--United States ;
Drug factories--Enivronmental aspects--Standards--United States ;
Effluent quality--Standards--United States ;
Water--Pollution--United States--Point source identification
|
Additional Subjects |
Drug industry ;
Water pollution control ;
Economic impact ;
Chemical effluents ;
Industrial plants ;
Pollution regulations ;
Cost benefit analysis ;
Pharmaceutical industry
|
Internet Access |
|
Holdings |
Library |
Call Number |
Additional Info |
Location |
Last Modified |
Checkout Status |
EJAD |
EPA 821/R-95-017 |
|
Region 3 Library/Philadelphia, PA |
10/10/1997 |
EJBD |
EPA/821-R-95-017 |
|
Headquarters Library/Washington,DC |
12/19/2013 |
ELBD ARCHIVE |
EPA/821-R-95-017 |
Received from HQ |
AWBERC Library/Cincinnati,OH |
10/04/2023 |
NTIS |
PB95-219812 |
Some EPA libraries have a fiche copy filed under the call number shown. |
|
07/26/2022 |
|
Collation |
1 v. (various pagings) ; 28 cm. |
Abstract |
The report has been prepared to comply with Executive Order 12866, which requires federal agencies to assess the costs and benefits of each significant rule they propose or promulgate. The regulations for the pharmaceutical industry, which are proposed by the U.S. Environmental Protection Agency (EPA, or the Agency), meet the Order's definition of a significant rule. The Agency has assessed both costs and benefits of the proposed rule, as presented in this Regulatory Impact Assessment (RIA). |
Notes |
"February 1995." "EPA 821-R-95-017"--Cover. Includes bibliographical references. |